US OptionsDetailed Quotes
SCLX240816C1500
- 0.50
- -0.55-52.38%
15min DelayTrading Jul 22 09:55 ET
0.50High0.50Low
0.50Open1.05Pre Close8 Volume3 Open Interest1.50Strike Price400.00Turnover269.67%IV12.68%PremiumAug 16, 2024Expiry Date0.28Intrinsic Value100Multiplier25DDays to Expiry0.23Extrinsic Value100Contract SizeAmericanOptions Type0.7222Delta0.2670Gamma2.96Leverage Ratio-0.0085Theta0.0005Rho2.14Eff Leverage0.0016Vega
Scilex Holding Stock Discussion
Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido® Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region
Scilex Holding Company (Nasdaq: SCLX) has entered a Memorandum of Understanding (MOU) with ACEA Therapeutics for collaboration on ZTlido®, a lidocaine topical system for neuropathic pain relief. The a...
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
▪️The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the Internation...
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies
Scilex Holding Company (Nasdaq: SCLX) has entered into a commitment letter with Perigrove and Graf Holdings for a $100 million 5-year term financing with royalty-based payments. The funds will be used primarily to repay an existing $85 million senior secured loan from Oramed Pharmaceuticals...
No comment yet